Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Weifeng Xu, Ph.D.

Senior Research Investigator at Bristol-Myers Squibb


Four years ago, Weifeng was recruited to BMS as the first dedicated person to develop cell-based neutralizing Ab assay, which is critical to characterize whether the anti-drug antibody developed by clinical patient can neutrlize/reduce drug efficacy. This is challenge, since the cells used in the assay needs to be closely related to the Mechanism of Action of the drug, in addition, both patient serum factors and injected drug can interfere with the assay, as Weifeng will discuss later. So far Weifeng has developed and validated multiple cell-based NAb assays for some of the most important pipeline at BMS. Among them are Yervoy and Opdivo, both have been approved by FDA and dominate current immunoregulary cancer therapy market.

Agenda Sessions